The first clinical trial to test whether drug regimens containing Selzentry/Celsentri (maraviroc) from Viiv HealthCare, are also safe and tolerable...
The 48-week results from the Phase III MODERN study comparing Celsentri/Selzentry (maraviroc), from ViiV Healthcare, dosed once daily with darunavir/ritonavir...